-
The ADC field has entered a stage of rapid development, and target competition has become the key
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] Recently, the CDE website showed that AstraZeneca/Daisankyo’s HER2-targeting antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) was declared for listing in China, with unknown indications .
In addition, Enhertu is the first ADC drug approved by the FDA for the treatment of HER2-positive gastric cancer .
-
The field of oncology has become a decisive "highland" for a large number of multinational pharmaceutical companies
Time of Update: 2022-04-15
From the perspective of the clinical pipelines of major pharmaceutical companies, tumors are also the focus of new drug research and development .
-
Innovative traditional Chinese medicine drugs may usher in an outbreak, and several major bottlenecks remain to be resolved
Time of Update: 2022-04-15
At present, the traditional Chinese medicine technical equipment industry still has difficulties such as low investment in research and development, lack of research talents, limited key technologies, and backward enterprise management .
-
The market of traditional Chinese medicine continues to improve, and these companies are worthy of attention
Time of Update: 2022-04-15
Among them, it is worth mentioning that the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development" jointly issued by the State Drug Administration and other 8 departments earlier clearly proposed that new steps should be taken in the inheritance, innovation and development of traditional Chinese medicine.
-
In 2030, the domestic in vitro diagnostic market will reach 288.2 billion yuan, and the space to replace the import of high-end production equipment is to be opened
Time of Update: 2022-04-15
It is understood that in the medical and health field, the main product of Kerui Technology is the automatic filling line equipment for in vitro diagnostic reagents (IVD), but it currently accounts for a small amount of the company's overall revenue .
-
How should local new drugs go overseas?
Time of Update: 2022-04-15
Judging from the achievements of local new drugs in the process of going overseas, there are currently 5 local innovative drugs that have been successfully approved abroad, including the prescription drug Kanglaite injection for the treatment of cancer, BeiGene's zanubrutinib, and Frontier Bio's Aibo Weitai, Chidamide from Microchip Bio, and Prokalutamide from Kintor Pharmaceuticals, etc.
-
The Chinese medicine industry welcomes favorable policies, and new drugs will be launched at an accelerated pace
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In order to encourage the innovation of traditional Chinese medicine and promote the development of traditional Chinese medicine, the state has issued a series of policy measures in recent years .
-
Next week, a new pharmaceutical stock will be subscribed for, focusing on APIs and preparations!
Time of Update: 2022-04-15
7424 million yuan respectively, with a three-year compound annual growth rate of net profit attributable to the parent company of 10.
54%; the company's net profit attributable to the parent was 34 million yuan, a year-on-year growth rate of 2.
-
The "14th Five-Year" Chinese medicine development plan deploys ten key tasks, and the industry development will usher in qualitative changes
Time of Update: 2022-04-15
Analysts said that the introduction of the "14th Five-Year Plan" for traditional Chinese medicine will promote the development of the industry and usher in a qualitative change .
-
The market of Chinese herbal decoction pieces continues to expand, and quality improvement becomes the focus of development
Time of Update: 2022-04-15
In this context, in the future, all pharmaceutical companies need to further strengthen self-discipline, and strictly follow the requirements of the new version of the Pharmacopoeia, and do a good job in planting, production, processing, circulation and other aspects of the check work, in order to better ensure the safety of traditional Chinese medicine pieces, help Promote the improvement of the overall quality of the Chinese herbal medicine industry .
-
Pharmaceutical companies actively deploy the API business and build the integrated advantage of API preparations
Time of Update: 2022-04-15
[Pharmaceutical Network Market Analysis] In recent years, under the refined division of labor in the global pharmaceutical industry, as the upstream of chemical preparations, the pharmaceutical intermediates and chemical API industries have achieved rapid development .
-
The Chinese medicine sector strengthened, and Xinguang Pharmaceutical rose nearly 15%
Time of Update: 2022-04-15
As of February 24, a number of proprietary Chinese medicine companies have released their 2021 performance reports, including Pien Tze Huang, Shou Xian Gu, Ji Chuan Pharmaceutical, etc.
-
In the first half of the year, the market of Chinese medicinal materials was still at a high level, and the prices of a large number of varieties continued to rise.
Time of Update: 2022-04-15
According to relevant data, among the 1,445 varieties monitored by the market, there were 55 varieties of Chinese medicinal materials whose prices rose in March .
-
In the new year, B-class pharmaceutical stocks fell for four consecutive days
Time of Update: 2022-04-15
Due to the high stickiness of the CDMO industry, according to the company's "Follow "Molecules win molecules" strategy, and it is expected that the company's market share in the later stages will gradually increase as these projects funnel into the late clinical and commercial stages .
-
Chinese medicine presents a new development pattern, how to grasp the main line?
Time of Update: 2022-04-15
For example, Ping An Securities looks at opportunities in the TCM industry from five main lines, including innovative TCM drugs, branded OTC TCM, TCM formula granules, TCM injections, and TCM medical services .
-
Under the continuous transformation and upgrading of the pharmaceutical industry, personnel changes will become more frequent
Time of Update: 2022-04-15
In addition to AstraZeneca, many multinational pharmaceutical companies have also undergone major personnel adjustments this year: for example, the head of the Novartis Oncology Hematology Division resigned; the position of the head of the Takeda Oncology Division was finally settled after 2 months of vacancy ; Fresenius Kabi China changed its chief financial officer; Abbott's global vice president resigned, etc.
-
Another batch of large-variety drug price cuts!
Time of Update: 2022-04-15
For example, on February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions .
34 drugs produced by 28 pharmaceutical companies ushered in price reductions.
-
This year, a large number of drugs will be transferred out of medical insurance
Time of Update: 2022-04-15
For example, the "Announcement on Chongqing Municipality's Gradual Digestion of the List of Locally Supplemented Medical Insurance Class B Drugs" issued by the Chongqing Municipal Medical Insurance Bureau stipulates that the real estate drugs with purchased data and those produced and sold by local pharmaceutical companies and whose sales ratio exceeds 20% in Chongqing Other non-property drugs are included in the final year of digestion .
-
Recently, pharmaceutical companies are starting the pace of intensive listing!
Time of Update: 2022-04-15
In addition, according to the "Initial Public Offering of Stocks on the Science and Technology Innovation Board Listing Announcement" previously issued by First Pharmaceutical Holdings, it will also be listed on the Shanghai Stock Exchange on March 23, 2022, at a price of 39.
-
The net worth of several pharmaceutical securities investment funds rose
Time of Update: 2022-04-15
[Pharmaceutical Network Pharmaceutical Stock Market] On March 23, the net value of a number of pharmaceutical securities investment funds rose, including Huatai Pineapple Biomedical Mixed C, Southern Pharmaceutical Innovation Stock A, E Fund Biomedical Biostock A, Fuguo Biomedical Technology Mixed C, Galaxy Medicine Mixed, Cinda Australia Silver Medicine and Health Mix, etc.
